COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Print this page

COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

1. To determine whether carboplatin radiosensitization increases long term event-free survival for high risk medulloblastoma/PNET patients.
2. To determine whether Isotretinoin increases long term event-free survival for high risk medulloblastoma/PNET patients.
3. To compare residual disease response to radiation alone versus radiation plus carboplatin.
4. To identify molecular prognostic indicators suitable for patient stratification in future trials.
5. To evaluate the HRQOL during phases of active treatment specific to treatment modalities.
6. To describe the neuropsychological functioning of the study population and to evaluate the relationship
between neuropsychological status and health related quality of life.

Protocol Number: 110712
Phase: Phase III
Applicable Disease Sites: Brain and Nervous System
Drugs Involved: CISPLATIN
VINCRISTINE
ISOTRETINOIN
CARBOPLATIN
CYCLOPHOSPHAMIDE
Principal Investigator: Richard Drachtman
Scope: National
Therapies Involved: Chemotherapy multiple agents systemic
Chemotherapy single agent systemic
Radiotherapy
Participating Institutions: Robert Wood Johnson University Hospital in New Brunswick
Rutgers Cancer Institute of New Jersey
Robert Wood Johnson Medical School

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@cinj.rutgers.edu.

Donate Now

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health